Post-COVID syndrome, often called long COVID, describes a broad collection of symptoms that persist or emerge after the acute infection has passed. Patients may experience exhaustion, shortness of breath, rapid or irregular heartbeats, chest discomfort, impaired concentration and reduced exercise capacity. The condition is biologically diverse, and researchers have implicated several overlapping mechanisms, including immune dysregulation, damage to the vascular lining, abnormal clotting, autonomic nervous-system disturbances and persistent inflammation. In some patients, imaging and laboratory studies also suggest that the heart can remain affected even when conventional tests appear normal.

The trial focuses on cardiac inflammation, a process in which immune activity can damage or disrupt heart muscle and the tissues surrounding it. Inflammation may interfere with the contraction of cardiomyocytes, alter the electrical properties of the heart and impair the function of small blood vessels that supply cardiac tissue. Magnetic resonance imaging can detect patterns such as myocardial edema, fibrosis or abnormal tissue enhancement, while blood tests may identify cellular stress or injury. These measurements are important because symptoms alone cannot reliably distinguish inflammatory heart disease from deconditioning, lung damage, anxiety or other consequences of viral infection.

Losartan belongs to a class of medicines known as angiotensin-receptor blockers. It inhibits the action of angiotensin II, a hormone that constricts blood vessels and contributes to blood pressure regulation. Excessive or prolonged activation of the renin–angiotensin system has also been associated with vascular dysfunction, oxidative stress, fibrosis and inflammatory signaling. By blocking the angiotensin II type 1 receptor, losartan can reduce some of these effects. The drug is already widely used for hypertension and certain forms of cardiovascular and kidney disease, making its safety profile better established than that of many experimental treatments.

Prednisolone takes a different pharmacological route. It is a synthetic glucocorticoid that enters cells and changes gene transcription, broadly suppressing the production and activity of inflammatory mediators. Corticosteroids can reduce immune-cell activation, tissue swelling and cytokine signaling, but their wide-ranging effects also mean that treatment must be carefully balanced. Potential concerns include elevated blood glucose, susceptibility to infection, mood changes, fluid retention and other complications, particularly when treatment is prolonged or given to people with underlying health risks.

Testing the two medicines in a controlled clinical trial is crucial because biological plausibility does not guarantee clinical benefit. A drug may improve a laboratory marker without improving fatigue, exercise tolerance or quality of life, or it may help one subgroup of patients while offering little value to another. The randomized design helps distribute known and unknown factors between treatment groups. Participants are assigned by chance, reducing the likelihood that differences in age, illness severity, previous medical conditions or time since infection will distort the comparison.

The double-blind structure adds another layer of protection against bias. Neither participants nor the investigators assessing them know who receives active treatment and who receives placebo during the blinded phase. This matters particularly in post-COVID research, where symptoms can fluctuate and expectations about treatment may influence how patients report their health. Placebo comparison also allows researchers to separate a genuine pharmacological effect from the natural recovery that occurs in some people, as well as from the benefits of medical attention and structured follow-up.

The trial’s importance extends beyond these two medications. SARS-CoV-2 can affect the cardiovascular system through direct injury, immune-mediated damage, endothelial dysfunction and disturbances in coagulation. Yet persistent symptoms do not necessarily arise from the same mechanism in every patient. A treatment that targets angiotensin signaling may be most relevant to vascular or myocardial changes, whereas an anti-inflammatory steroid may be more useful when immune activation is prominent. Carefully characterized trials could therefore help move long-COVID care away from a single universal treatment and toward biologically defined, individualized strategies.

The citation identifies the work as a randomized, double-blind, placebo-controlled investigation of losartan and prednisolone, but the bibliographic information provided here does not include numerical results, participant outcomes or the authors’ final estimates of treatment effectiveness. Those details are essential for judging whether either drug improved symptoms, cardiac imaging findings or biomarkers, and for assessing possible adverse effects. Until the complete trial data are examined, the study should be understood as evidence from a structured clinical test of two therapeutic approaches—not as proof that either medicine is an established treatment for post-COVID syndrome. Its broader contribution lies in applying rigorous cardiovascular and immunological methods to a persistent consequence of viral disease.

Subject of Research: Post-COVID syndrome and cardiac inflammation

Article Title: Losartan and prednisolone for post-COVID syndrome and cardiac inflammation: a randomized, double-blind, placebo-controlled trial

Article References: Puntmann, V.O., Nagel, E., Beitzke, D. et al. Losartan and prednisolone for post-COVID syndrome and cardiac inflammation: a randomized, double-blind, placebo-controlled trial. Nat Commun 17, 7599 (2026). https://doi.org/10.1038/s41467-026-75991-w

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41467-026-75991-w

Keywords: Post-COVID syndrome, long COVID, cardiac inflammation, SARS-CoV-2, losartan, prednisolone, cardiovascular disease, randomized controlled trial

Post-COVID syndrome, also referred to as long COVID, encompasses a constellation of persistent and debilitating symptoms such as profound fatigue, myalgia, arthralgia, and general malaise, which manifest following acute SARS-CoV-2 infection. These symptoms are increasingly understood to stem from immune dysregulation, wherein the immune system exhibits hyperactivity or aberrant targeting of host tissues. Dr. Daynes articulates that in this maladaptive response, immune cells may erroneously attack healthy cells or mount disproportionate reactions to benign stimuli, engendering chronic systemic inflammation that underpins the clinical symptomatology of post-COVID syndrome.

The clinical trial enrolled 31 patients who had been hospitalized for COVID-19 and subsequently diagnosed with post-COVID syndrome. Participants were randomized into two groups: one cohort engaged in an eight-week, supervised exercise-based rehabilitation program integrating treadmill walking, cycling, and strength training; the other received standard medical care without structured physical activity. This methodological design enabled a rigorous comparison of immune parameters between physically rehabilitated patients and controls, establishing a causal relationship between exercise and immune modulation post-COVID.

Immunophenotyping analyses revealed that patients who underwent the exercise intervention exhibited marked enhancements in the population of naïve immune cells. These cells play a pivotal role in recognizing novel pathogens and initiating adaptive immune responses. Moreover, there was a notable increase in central memory CD4+ T cells among the exercisers, cells that are crucial for rapid and robust responses upon re-exposure to previously encountered antigens, including SARS-CoV-2. This shift towards a more functional memory T cell repertoire indicates a restored capacity for effective immune surveillance and response.

Further immunological improvements were detected in central and effector memory CD8+ T cells. These cytotoxic lymphocytes are responsible for targeting and eliminating infected cells swiftly upon recognition of viral antigens. The augmentation of both central and effector memory subsets suggests that exercise not only bolsters immediate effector responses but also enhances long-term immunological memory, which is essential for protection against reinfection. Such findings underscore the systemic benefits of exercise-mediated immunomodulation in post-COVID convalescents.

Mechanistically, Dr. Daynes hypothesizes that exercise facilitates these immune improvements through multiple physiological pathways. Enhanced cardiovascular function resulting from exercise increases blood flow and shear stress, promoting the mobilization and circulation of immune cells. The biomechanical stimuli also encourage immune cells to traverse vascular and lymphatic tissues more efficiently, enhancing their ability to detect and respond to pathogens. Additionally, exercise-induced modulation of cytokine profiles may reduce chronic inflammation and foster an immunological environment conducive to tissue repair and homeostasis.

Beyond improved immune cell distribution and function, exercise is posited to enhance intercellular communication within the immune system. This facilitates refined coordination of innate and adaptive immune responses, crucial for resolving chronic inflammation without exacerbating tissue damage. The increased turnover and production of immune cells stimulated by physical activity also replenish the immune repertoire, replacing exhausted or dysfunctional cells with newly generated ones that restore the balance between pro-inflammatory and regulatory elements.

The significance of this research extends beyond biomolecular insights to tangible clinical implications. Post-COVID syndrome affects individuals across age groups and can severely impair quality of life by limiting capacity for work, study, and routine activities. The rehabilitative exercise program offers an accessible and non-pharmacological intervention that may alleviate persistent symptoms by addressing their immunological root causes. This modality holds promise as an adjunct therapy to conventional symptomatic management, potentially reducing the long-term burden of long COVID.

Importantly, the investigators aim to expand future research to include patients who experienced milder COVID-19 illness not necessitating hospitalization. Determining whether similar immunological and symptomatic benefits of structured exercise manifest in this broader population will be critical for establishing generalized rehabilitation guidelines. The heterogeneity of post-COVID syndrome presentations underscores the need for stratified therapeutic approaches tailored to individual patient profiles and disease severity.

Independent commentary by Dr. Guido Vagheggini, an expert in respiratory clinical care and physiology, highlights the broader clinical relevance of these findings. Dr. Vagheggini emphasizes the pervasive impact of post-COVID syndrome and the urgent need for interventions that restore immune function, thereby reducing symptom burden and mitigating fears of recurrent infections. He applauds this trial’s contribution to understanding the mechanistic underpinnings of exercise-induced immune restoration and its potential role in public health strategies addressing long COVID.

The study’s robust randomized controlled design enhances the validity of its conclusions and sets a precedent for future immunological studies integrating clinical and molecular endpoints in post-infectious syndromes. By bridging the gap between physiology, immunology, and rehabilitation medicine, this work establishes physical exercise as a cornerstone in the multidisciplinary approach needed to tackle the complex sequelae of COVID-19.

As post-COVID syndrome becomes a growing public health challenge, these insights offer hope and direction. Encouraging controlled, supervised exercise regimens could become a standard element in the recovery protocols for patients enduring the protracted effects of COVID-19. This approach aligns with a broader movement to harness lifestyle interventions for immune system optimization and resilience in the face of ongoing viral threats.

In conclusion, the data from Dr. Daynes and colleagues provide compelling evidence that exercise-based rehabilitation exerts significant restorative effects on central and memory T cell populations in post-COVID syndrome patients, mediating improved immune surveillance and function. This novel therapeutic avenue promises to ameliorate symptoms associated with immune dysregulation and enhance long-term immunity against SARS-CoV-2 and other pathogens, marking a milestone in post-COVID clinical care and research.

Subject of Research: People

Article Title: Exercise-Induced Immune Recalibration in Post-COVID Syndrome: A Randomized Controlled Trial

Image Credits: Enya Daynes/ERS

Keywords: COVID 19, Respiratory disorders, Physical exercise